Enlivex Therapeutics Ltd. (TLV:ENLV)
Israel
· Delayed Price · Currency is ILS · Price in ILA 364.60
+12.40 (3.52%)
Apr 3, 2025, 5:24 PM IDT
Enlivex Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
Cash & Equivalents | 3.3 | 0.81 | 49.95 | 11.2 | 5.67 | Upgrade
|
Short-Term Investments | 20.2 | 26.51 | 0.3 | 72.93 | 30.03 | Upgrade
|
Cash & Short-Term Investments | 23.5 | 27.32 | 50.24 | 84.13 | 35.71 | Upgrade
|
Cash Growth | -14.00% | -45.63% | -40.28% | 135.61% | 197.36% | Upgrade
|
Other Receivables | - | 0.23 | 0.65 | 1.2 | - | Upgrade
|
Receivables | - | 0.23 | 0.65 | 1.2 | - | Upgrade
|
Prepaid Expenses | 2.3 | 1.11 | 1.44 | 1.11 | 1.24 | Upgrade
|
Restricted Cash | - | - | - | - | 1.17 | Upgrade
|
Other Current Assets | 0.2 | 5.11 | - | - | - | Upgrade
|
Total Current Assets | 25.99 | 33.76 | 52.33 | 86.44 | 38.12 | Upgrade
|
Property, Plant & Equipment | 0.63 | 10.2 | 14.9 | 8.22 | 2.14 | Upgrade
|
Other Long-Term Assets | 1.07 | -7.14 | 0.41 | 0.49 | 0.1 | Upgrade
|
Total Assets | 27.69 | 36.83 | 67.64 | 95.15 | 40.36 | Upgrade
|
Accounts Payable | 0.81 | 0.83 | 1.95 | 0.88 | 0.46 | Upgrade
|
Accrued Expenses | 2.85 | 3.66 | 4.01 | 3.22 | 2.54 | Upgrade
|
Current Portion of Leases | - | 0.35 | 0.65 | 0.62 | 0.2 | Upgrade
|
Other Current Liabilities | 0.14 | 1.23 | - | - | 1.17 | Upgrade
|
Total Current Liabilities | 3.8 | 6.06 | 6.61 | 4.72 | 4.37 | Upgrade
|
Long-Term Leases | - | 0.69 | 4.19 | 5.39 | 0.5 | Upgrade
|
Other Long-Term Liabilities | 0.3 | - | - | - | - | Upgrade
|
Total Liabilities | 4.1 | 6.75 | 10.8 | 10.11 | 4.87 | Upgrade
|
Common Stock | 2.69 | 2.14 | 2.12 | 2.11 | 1.65 | Upgrade
|
Additional Paid-In Capital | 146.91 | 138.94 | 136.65 | 133.8 | 70.36 | Upgrade
|
Retained Earnings | -127.11 | -112.09 | -83.03 | -51.97 | -37.5 | Upgrade
|
Comprehensive Income & Other | 1.1 | 1.1 | 1.1 | 1.1 | 0.98 | Upgrade
|
Total Common Equity | 23.59 | 30.08 | 56.84 | 85.04 | 35.49 | Upgrade
|
Shareholders' Equity | 23.59 | 30.08 | 56.84 | 85.04 | 35.49 | Upgrade
|
Total Liabilities & Equity | 27.69 | 36.83 | 67.64 | 95.15 | 40.36 | Upgrade
|
Total Debt | - | 1.03 | 4.85 | 6.01 | 0.7 | Upgrade
|
Net Cash (Debt) | 23.5 | 26.29 | 45.4 | 78.12 | 35.01 | Upgrade
|
Net Cash Growth | -10.62% | -42.09% | -41.89% | 123.18% | 202.11% | Upgrade
|
Net Cash Per Share | 1.15 | 1.42 | 2.47 | 4.37 | 2.66 | Upgrade
|
Filing Date Shares Outstanding | 23.65 | 18.6 | 18.42 | 18.37 | 18.31 | Upgrade
|
Total Common Shares Outstanding | 23.65 | 18.6 | 18.42 | 18.33 | 14.59 | Upgrade
|
Working Capital | 22.19 | 27.7 | 45.72 | 81.72 | 33.75 | Upgrade
|
Book Value Per Share | 1.00 | 1.62 | 3.09 | 4.64 | 2.43 | Upgrade
|
Tangible Book Value | 23.59 | 30.08 | 56.84 | 85.04 | 35.49 | Upgrade
|
Tangible Book Value Per Share | 1.00 | 1.62 | 3.09 | 4.64 | 2.43 | Upgrade
|
Machinery | - | 3.36 | 3.38 | 2.34 | 1.53 | Upgrade
|
Leasehold Improvements | - | 8.67 | 8.61 | 1.52 | 0.71 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.